I write this editorial, several weeks after the editor's preferred deadline, at the annual meeting of the Society of Toxicology (SOT) in San Antonio, Texas. At this year's meeting, we had an excellent debate, on 11 March 2013, on the motion that "In the Near Foreseeable Future, Much of Toxicity Testing Can be Replaced by Computational Approaches". The motion was proposed by an SOT member and opposed by a member of the European Societies of Toxicology (EUROTOX). At the climax of an entertaining and lively debate, about three times the number of members of the audience voted against the motion than voted for it. However, the crux of the debate was not that computational toxicology is of no use, but what do "near" and "foreseeable" mean. Both debaters, and seemingly the majority of the very large audience, agreed that computational methods will be crucial to toxicology in the future. It's just that the issues are how we will get there, how long it will take, and who will pay for it.
This week also marked another important milestone, namely, the ban of marketing of products tested on animals for cosmetics ingredients within the European Union that came into force on 11 March 2013. 1 This, combined with the deadline of 31 May 2013 for the submission of REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) system dossiers to the European Chemicals Agency (ECHA) for compounds manufactured in, or imported into, the European Union at over 100 tonnes per year, 2 has resulted in an immense interest and research effort in computational toxicology. The European Union has resourced the research through the Framework Programmes at the cost of over 200 million euros. 3 This issue of ATLA marks the completion of one such initiative -the CADASTER project -and the aim of this editorial is to put CADASTER into the context of these broader efforts of computational toxicology. It is acknowledged that CADASTER is focused on environmental effects and endpoints, whereas computational toxicology in toto includes human health as well. But the issues and concerns are essentially the same, whatever the endpoint.
So, what is computational toxicology? The simple answer is that I am not sure that I know anymore! It is becoming an over-used and increasingly misunderstood phrase that seems much more commonplace in the new world of 21st Century Toxicology. 4 It seems to mean many things, so, inevitably, this editorial will lose, confuse or simply irritate some readers. In it, I am broadly discussing aspects such as the use of (Quantitative) Structure-Activity Relationship ([Q]SAR) modelling, category formation and read-across for toxicity prediction. These are some of the main issues covered by the excellent EU CADASTER project which are described in this issue. However, let's not forget that modelling for toxicity prediction goes well beyond my limited knowledge and what is described here -it potentially reaches into the world of systems biology and virtual organs and organisms! At the heart of modelling are the data. CADASTER has provided some insight into the databases available and has brought together data suitable for modelling. However, the reality is that with a very small number of exceptions (typically in acute aquatic toxicity), there are very few examples of public data sets of toxicity values that have been developed with modelling in mind, i.e. which are based around definable mechanisms of action or exploring chemical space. Consider, for instance, the analogous situation in drug discovery -medicinal chemists have been probing mechanisms and hypotheses by the directed synthesis of compounds and testing for decades. This is one possible aspect that needs to be picked up -in other words, the use of intelligent testing to betterdefine the chemical space associated with a mechanism. This is something now being put forward as part of the Adverse Outcome Pathway paradigm.
Whilst we don't have the exact data sets we require, we are definitely gaining access to more data and more information. To illustrate the possibilities and variety of sources, consider the depth and complexity of the OECD's eChemPortal, 5 the rich data resources of the OECD QSAR Toolbox, 6 or the detailed toxicogenomics data in the Open TG-GATEs database. 7 All are relatively recent innovations, are all freely available, and they all provide the possibility of data mining and model-ling. Therefore, the developing challenge is not that we have too few data to model, but that we now need to consider how to curate the data, store them in useful and usable databases, determine those data that may be considered 'reliable', and cope with duplicate and contradictory data. Lastly, if we are in a situation where we have the data in a suitable format, how are we going to mine these data to get models or predictions from them?
CADASTER has focused on particular efforts in QSAR modelling. With the increasing 'popularity' of grouping and read-across, should we begin to wonder if the days of grandiose QSARs are over? CADASTER shows that the answer is, probably not -that there is still a purpose for model development and application. What is interesting, whether or not by serendipity, is that CADASTER has focused its efforts on the modelling of four groups of compounds (the polybrominated diphenylethers, perfluoroalkylated substances and their transformation products, substituted musks/ fragrances and the triazoles/benzotriazoles), rather than attempting to model the chemical, or at least the REACH-registered, universe.
This leads to an important point about how we should use QSAR models. Being myself trained in the 'classical school' of QSAR, I must draw attention to the fact that it is almost two years since the death, in May 2011, of Professor Corwin Hansch. He is credited with the first publication in what is now known as 'QSAR'. 8 Increasingly, many do not know Hansch's name or philosophy. However, it is worth going back to his 'principles'. He was attempting to rationalise biological activity, in order to guide the better use of resources. His initial studies took restricted data sets of pesticides with a single mechanism of action, high-quality biological data, and very relevant and measured physicochemical properties. Good, mechanistically-based models were formed. These models were interpretable and related strongly to the effects being modelled. It is intrinsically clear that they were not to be extrapolated outside the chemistry of the molecules on which they were developed, and that the model was specific for this endpoint, effect and test. In terms of what Hansch's pioneering modelling did, there is little to add, other than to take forward his principles of mechanistic interpretability and transparency, endpoint specificity, restricted domain, and simplicity (except to say than no-one today would measure these parameters). This is sometimes called the use of local, as opposed to global, models. Has the use of QSARs for toxicity prediction progressed since the early 1960s? In many waysno! For regulatory purposes, in most instances we are increasingly stuck with simplistic groupings (often the ultimate local models) for read-across. However, the mantra for successful application must be interpretability and the mechanistic relevance of our models.
The partners in CADASTER have led the way in their project, by providing freely available software -so-called 'open-access' models that can be used by anyone. To make predictive toxicology more attractive, this is one of the cornerstones of moving the science forward. The quality and the freely accessible nature of the OECD QSAR Toolbox, 6 United States Environmental Protection Agency's (US EPA's) EPI Suite, 9 and the European Commission's Joint Research Centre's (JRC's) Toxtree software, 10 among others, were undoubtedly the key to the uptake of read-across for REACH submissions recently discussed. 11 However, there is still a place for high-quality, welldeveloped and well-maintained 'commercial' or 'not-for-profit' software. There are a number of companies who provide such services, such as Lhasa Ltd, MultiCASE Inc., ACD/Tox Suite, and the Laboratory of Mathematical Chemistry, to name but a few. 12 The desire for freely-available software should not blind us to the need for highquality products for toxicity prediction.
The design of the CADASTER project greatly acknowledges the Integrated Testing Strategy (ITS) 13 philosophy. This is the collection and integration of different types and levels of information. For toxicity prediction to work in the future, models and modelling will need greater and better integration, and weight-of-evidence (WoE) approaches will need to be used more extensively. We must not be frightened (although we should be aware of the limitations) of making assessments on the basis of low-quality data. Building consensus into our data collection and interpretation will be crucial, as will the breaking down of the constructs that say 'one compound, one prediction, job done'. Tools such as those presented by CADASTER are good examples of models that could be applied as part of a battery.
The question of the regulatory acceptability of predictions from computational toxicology is not easy to address. What this often comes down to is this: Would you accept a prediction for a low-dose, subtle effect (e.g. a reproductive toxicity endpoint), if you had little confidence in it, especially when you know that closely-related molecules may have widely differing activities? This is a strong argument against the use of computational models in isolation. Therefore, when will we be able to use computational models, and for what types of endpoints? Inevitably, this is best answered as being context dependent -i.e. depending on the chemical and the endpoint. Predictions for compounds clearly 'similar' to other toxic compounds, and being predicted as being toxic, are likely to be accepted. The ECHA, among others, has provided guidance on the use of predictions from models. 14 We are guided by the well-established OECD Principles for the Validation of (Q)SARs -i.e. defining the model, ensuring the molecule is in the applicability domain, etc. -but what will really be required for regulatory acceptance is that the prediction can be justified. Justification of a prediction is more than simply documenting it -it is the expert analysis and interpretation to explain why we can have confidence in a particular prediction. This includes the reasons for claiming that the model is relevant and correct, and why the prediction is acceptable.
In a world where we have the results of EU projects, including the considerable efforts of CADASTER, available in the form of databases and models, a great need exists to ensure that there is a proper legacy from this work. There is no easy solution to this. It is unrealistic to expect databases and predictive models to be future-proof, so either we must anticipate a resource to store the data and models from projects such as CADASTER, and strive to record the results and data in a format that can be taken up by others, or we must ensure that long-term maintenance is effectively built into a project. None of these, or indeed any other, solutions are ideal. Some resources are available, e.g. the US EPA's excellent DSSTox database. 15 However, there is often a 'hope' (if not an expectation) among many, that the EC's JRC or the OECD will provide this resource, but without having the means of doing it. A realistic objective must be to leave data and models, etc., in a form that can be taken up by others. Complex databases can be 'flattened' into Excel ® spreadsheets or tab-delimited text files that can be read into future databases; models can be reported in detail for others to code into relevant software (the OECD QSAR Reporting Format, 16 whilst not perfect, may provide a means of achieving this).
If we have some idea of the complexity of computational toxicology, we can assume its importance, but we must also consider its challenges. In terms of endpoints, it is the modelling of chronic, low-dose toxicities that represent one of the most significant immediate (albeit long-term) challenges. At this point, we should be realistic and consider the effects of single chemical substances -the modelling of mixture toxicity will only be possible when predictions for single chemicals are good and a means of estimating the effects of mixtures is established. Acceptance of predictions from models for regulatory purposes is also a challenge that needs to be faced head-on. There is no point in modelling and encouraging predictions for regulatory purposes, unless a framework exists for their acceptance. Please note, this is not a call for a validation-led exercise to validate models, but a recommendation that 'valid' predictions can be defined, identified and accepted, with predictions of lower confidence requiring more evidence or justification. Other challenges abound, notably: the need for a better understanding of how and when to use biokinetics modelling for in vitro to in vivo extrapolation; modelling the toxicity of nanoparticles; a move toward global acceptance of predictions and modelling techniques -for instance, how will they be used in Brazil, China, India, etc? What projects such as CADASTER provide us with are both the models to take forward and the approaches needed for using such models.
The second part of the debate on the motion that "In the Near Foreseeable Future, Much of Toxicity Test ing Can be Replaced by Computational Approaches", will be held at the Annual EUROTOX Congress in September 2013. It will be interesting to see how a predominantly European audience views this motion, after so much recent emphasis on the use of these methods for REACH system compliance. Will the next six months bring an even greater shift toward in silico models? We do need to ensure that there is greater visibility of the millions of euros from European taxpayers and consumers that is going toward the funding of this research. The results from the CADASTER project are a small, but significant, step forward in a very long path toward having computational methods at the centre of toxicology.
